key: cord-0920558-8qz5ptb3 authors: Nelson, David W.; Granberg, Tobias; Andersen, Pia; Jokhadar, Elias; Kåhlin, Jessica; Granström, Anna; Hallinder, Helena; Schening, Anna; Thunborg, Charlotta; Walles, Håkan; Hagman, Göran; Shams‐Latifi, Roya; Yu, Jimmy; Petersson, Sven; Tzortzakakis, Antonios; Levak, Nicholas; Aspö, Malin; Piehl, Fredrik; Zetterberg, Henrik; Kivipelto, Miia; Eriksson, Lars I. title: The Karolinska NeuroCOVID study protocol: Neurocognitive impairment, biomarkers and advanced imaging in critical care survivors date: 2022-04-02 journal: Acta Anaesthesiol Scand DOI: 10.1111/aas.14062 sha: 74de346bea1946d6faf6ddbba8e7af20b3363739 doc_id: 920558 cord_uid: 8qz5ptb3 BACKGROUND: This is the study plan of the Karolinska NeuroCOVID study, a study of neurocognitive impairment after severe COVID‐19, relating post‐intensive care unit (ICU) cognitive and neurological deficits to biofluid markers and MRI. The COVID‐19 pandemic has posed enormous health challenges to individuals and health‐care systems worldwide. An emerging feature of severe COVID‐19 is that of temporary and extended neurocognitive impairment, exhibiting a myriad of symptoms and signs. The causes of this symptomatology have not yet been fully elucidated. METHODS: In this study, we aim to investigate patients treated for severe COVID‐19 in the ICU, as to describe and relate serum‐, plasma‐ and cerebrospinal fluid‐borne molecular and cellular biomarkers of immune activity, coagulopathy, cerebral damage, neuronal inflammation, and degeneration, to the temporal development of structural and functional changes within the brain as evident by serial MRI and extensive cognitive assessments at 3–12 months after ICU discharge. RESULTS: To date, we have performed 51 3‐month follow‐up MRIs in the ICU survivors. Of these, two patients (~4%) have had incidental findings on brain MRI findings requiring activation of the Incidental Findings Management Plan. Furthermore, the neuropsychological and neurological examinations have so far revealed varying and mixed patterns. Several patients expressed cognitive and/or mental concerns and fatigue, complaints closely related to brain fog. CONCLUSION: The study goal is to gain a better understanding of the pathological mechanisms and neurological consequences of this new disease, with a special emphasis on neurodegenerative and neuroinflammatory processes, in order to identify targets of intervention and rehabilitation. The COVID-19 pandemic has posed enormous health challenges to individuals and health-care systems worldwide. An emerging feature of severe COVID-19 frequently being reported is that of temporary and extended neurological and cognitive impairment, exhibiting a myriad of symptoms and signs ranging from anosmia to severe encephalopathy and stroke. 1 The cause of this has not yet been fully elucidated, but several mechanisms have been proposed including hyperinflammation and immune responses as well as coagulopathy with endothelial damage leading to micro-and macrovascular embolization. 2 There is a growing awareness that cerebral inflammation and glial activation may be a consequence of systemic disease and even surgical trauma. 3 The degree to which COVID-19 directly affects the brain and cerebral vasculature or triggers secondary effects through systemic inflammation is yet unknown, but the evidence is emerging of high incidences of COVID-19-related neurological complications. 4, 5 Recently, in a case series of COVID-19 patients with neurological symptoms, there was an unusual pattern of marked CNS inflammation seen in cerebrospinal fluid (CSF). 6 Moreover, MRI of patients surviving COVID-19 displays a range of pathologies, however here also with possibly distinct pathophysiological profiles related to this new infection. 7 Critical illness neuropathy and myopathy also appear to be significant problems in moderate to severe COVID-19. 8 There is an urgent need to better understand the mechanisms of injury and pathophysiological processes in COVID-19 patients and their relations to brain imaging and long-term cognitive impairment. Identifying blood-borne biomarkers of neuronal injury, neurodegeneration, and inflammation is expected to be an important part of this process. 1 In this study, we aim to investigate patients treated for severe in the intensive care unit (ICU) to describe and relate serum-, plasma-and CSF-borne molecular and cellular biomarkers of inflammation, immune activity and coagulopathy, cerebral damage, neuronal inflammation, and degeneration, to the temporal development of structural and functional changes within the brain as evident by serial MRI and extensive cognitive assessments at 3-12-24 months after ICU discharge. The goal is to gain a better understanding of the pathological mechanisms and neurological consequences of this new disease, with a special emphasis on neurodegenerative and neuroinflammatory processes, as to identify targets of intervention and rehabilitation. This is an observational study of patients treated for severe COVID- systems worldwide. An emerging feature of severe COVID-19 is that of temporary and extended neurocognitive impairment, exhibiting a myriad of symptoms and signs. The causes of this symptomatology have not yet been fully elucidated. In this study, we aim to investigate patients treated for severe COVID-19 in the ICU, as to describe and relate serum-, plasma-and cerebrospinal fluid-borne molecular and cellular biomarkers of immune activity, coagulopathy, cerebral damage, neuronal inflammation, and degeneration, to the temporal development of structural and functional changes within the brain as evident by serial MRI and extensive cognitive assessments at 3-12 months after ICU discharge. To date, we have performed 51 3-month follow-up MRIs in the ICU survivors. Of these, two patients (~4%) have had incidental findings on brain MRI findings requiring activation of the Incidental Findings Management Plan. Furthermore, the neuropsychological and neurological examinations have so far revealed varying and mixed patterns. Several patients expressed cognitive and/or mental concerns and fatigue, complaints closely related to brain fog. The study goal is to gain a better understanding of the pathological mechanisms and neurological consequences of this new disease, with a special emphasis on neurodegenerative and neuroinflammatory processes, in order to identify targets of intervention and rehabilitation. biomarkers, brain injury, COVID-19, critical care, magnetic resonance imaging, neurocognitive disorders, patient outcome assessment CSF-borne molecular and cellular biomarkers of inflammation and coagulopathy, cerebral damage, neuronal inflammation and degeneration to MRI findings, and cognition at 3-12 months after ICU discharge. All patients ≥18 years of age having required intensive care due to PCR-positive COVID-19-related respiratory distress at the Karolinska University Hospital in Stockholm, Sweden, between March 2020 and June 2021, with biobanked plasma and serum samples during the ICU period and have been able to give study consent after intensive care, are eligible for inclusion. Initial serum biobanking was performed on patients treated for COVID-19 in the ICU as per local ethical approval (EPM 2020-01302). Written informed consent is obtained for study inclusion post-intensive care to analyze previously biobanked samples and data and perform prospective data collection, MRI, cognitive testing, and follow-up biosamples at 3-12 months post-discharge (EPM 2020-02760, EPM 2020-03802, EPM 2020-04282). Data have been collected structurally during the COVID-19 pandemic period in a local database at the Karolinska University Hospital from case notes and the local Patient Data Management Systems. This includes baseline characteristics, medication, physiological variables, laboratory samples, and treatments. Additional variables will be collected retrospectively from electronic health records. Serial plasma and serum samples have been collected at eight predefined time points during the intensive care and stored locally in the biobank for later analysis. Patients who participate in the prospective follow-up will provide additional samples at 3-, 6-and 12month follow-up. Whole-blood, plasma, and serum samples will be serially collected and stored for later molecular, cellular, and genetic analysis. CSF aliquots will be biobanked whenever a lumbar puncture is clinically indicated. Molecular and cellular markers of neuronal injury, neurodegeneration, and neuroinflammation will be analyzed along with markers of systemic inflammation, immune activity, and coagulopathy by comprehensive technical platforms. Biomarkers that will be measured on all plasma samples include neurofilament light and total tau as neuronal injury markers, as well as glial fibrillary acidic protein as an astrocytic activation marker. At the first visit, all participants are asked about the level of education, employment situation, general health, lifestyle, pre-existing medical conditions, symptoms suggestive of COVID-19 in the 7 days prior to the baseline visit, physical and cognitive function, and activities of daily living. To gain an understanding of participants' perception of cognitive status, the AD8 is used. 9 AD is a short, practical, and appropriate scale to distinguish between normal cognitive aging, mild cognitive impairment (MCI), or dementia for patients with memory complaints. if needed, and can be applied across different income groups, health systems, and country contexts (e.g., current COVID-19 status, definitions, and diagnostic criteria). All participants are offered advanced MRI assessment of the brain and lungs at the 3-and 12-month follow-ups, which complements routine clinical chest X-ray and computed tomography. All MRIs are performed on a Siemens Skyra 3 Tesla MRI scanner with a wide bore (70 cm), and participants will be able to listen to music and watch relaxing videos in order to improve patient comfort and reduce motion artifacts. This setup has been very much appreciated by the participants and is now synergistically also being implemented more broadly at our department clinically. The brain imaging protocol includes: • High-spatial resolution 3D anatomical T1-weighted and T2weighted FLAIR imaging. • Dedicated coronal STIR imaging for the olfactory bulbs and optic nerves. • High-angular resolution diffusion imaging for tractography. • Quantitative MRI (simultaneous PD, T1, and T2 mapping). 29 • Myelin quantification (Rapid Estimation of Myelin for Diagnostic Imaging, REMyDI). 30 • 3D Arterial Spin Labeling cerebral blood flow measurements. When possible (in relation to renal function): • An ultra-high-temporal resolution (670 ms) multi-band accelerated T2*-based dynamic susceptibility contrast-enhanced perfusion scan developed in-house. • Post-contrast 3D high-spatial resolution anatomical imaging with a special focus on leptomeningeal inflammation. And most importantly, based on our published data on COVID-19 31 and preliminary results from the 3-month follow-up, a novel sequence providing microscopic scale resolution for microvascular pathology: • Ultra-high-resolution (650 μm isotropic) 3D echo-planar susceptibility-weighted imaging. All imaging are reported in a structured manner by boardcertified radiologists and neuroradiologists, including assessments of atrophy, 32 white matter changes, 33 and SWI abnormalities. 34 A novel thoracic protocol MRI protocol is also applied, including short breath-hold sequences: • Anatomical 2D T2-weighted imaging. • Ultra-short echo time 3D imaging. • Look-locker T1-mapping (pre-and post-contrast, when possible). • An ultra-high-temporal resolution (430 ms) accelerated T1-based contrast-enhanced perfusion scan. Up to 100, and with a minimum goal of 40, patients are to be included and are expected to consist of a male and female mix related to the clinical cohort where approximately 75% are males. Mirroring the clinical cohort, the mean age is expected to be close to 60 years of age. The study is exploratory and hypothesis generating a formal power analysis is not readily applicable. However, as the analysis plan includes dimensionality reduction with methods such as PCA analysis and clustering methods, the number of composite variables This study is an observational study with an in-depth biochemical, neuropsychological analysis and radiological follow-up. Thus, given the limited number of patients, this study is hypothesis generating. Methods of data reduction and composite pattern recognition will need to be employed to limit the degrees of freedom and risk of type I error. This will include PCA and cluster analysis. Composite patterns or clusters of biomarkers will be related to MR findings and outcome assessments using regression techniques. revealing an acute cortical microinfarct in the left parietal lobe. Subacute cortical microinfarct with blood-brain barrier disruption revealed on a contrastenhanced 3D T1-weighted image (C). Here, we present the study plan of the ongoing Karolinska NeuroCOVID study. Understanding the mechanisms of neurocognitive manifestations in COVID-19 is needed to identify potential targets of intervention. This, in turn, could lead to better long-term treatments and rehabilitation, thus possibly contributing to reducing the long-term personnel and socioeconomic burden of this pandemic. This granular study is anticipated to help gain specific knowledge on the pathophysiological mechanisms, and radiological and long-term cognitive manifestations, of severe COVID 19 disease. These initial reports from MRI imaging also stress the need for having management plans for incidental findings in these kinds of studies and highlight the clinical value of close monitoring of the often vulnerable COVID-19 critical care survivors. All authors have been involved in both study planning, data collection, and manuscript writing. ClinicalTrials.gov Identifier: NCT04578197. Blood Biomarkers for detection of brain injury in COVID-19 patients Pathological findings in COVID-19 as a tool to define SARS-CoV-2 pathogenesis. A systematic review Association between cerebrospinal fluid biomarkers of neuronal injury or amyloidosis and cognitive decline after major surgery 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records SARS-CoV-2 and stroke characteristics: a report from the multinational COVID-19 Stroke Study Group CSF biomarkers in patients with COVID-19 and neurological symptoms: a case series Neurological associations of COVID-19 Neuromuscular involvement in COVID-19 critically ill patients Patient's rating of cognitive ability: using the AD8, a brief informant interview, as a selfrating tool to detect dementia The AD8: a brief informant interview to detect dementia Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results Movement disorder society task force on rating scales for Parkinson's disease. The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations SmellSpace: an odor-based social network as a platform for collecting olfactory perceptual data Smell and taste dysfunction in patients with COVID-19: a systematic review and meta-analysis COVID-19 Clinical Data Platform for clinical characterization and management of patients with suspected or confirmed COVID-19 Rey's verbal learning test: normative data for 1855 healthy participants aged 24-81 years and the influence of age, sex, education, and mode of presentation Adult norms for the Rey-Osterrieth Complex Figure Test and for supplemental recognition and matching trials from the Extended Complex Figure Test FAS and CFL forms of verbal fluency differ in difficulty: a meta-analytic study Neural systems supporting lexical search guided by letter and semantic category cues: a selfpaced overt response fMRI study of verbal fluency Neuropsychological decline in frontotemporal lobar degeneration: a longitudinal analysis What do verbal fluency tasks measure? Predictors of verbal fluency performance in older adults Short test of semantic and phonological fluency: normal performance, validity and testretest reliability Trail Making Test A and B: normative data stratified by age and education Wechsler adult intelligence scale-Fourth Edition A selfassessment questionnaire for mental fatigue and related symptoms after neurological disorders and injuries The hospital anxiety and depression scale The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection Clinical feasibility of synthetic MRI in multiple sclerosis: a diagnostic and volumetric validation study Validation of rapid magnetic resonance myelin imaging in multiple sclerosis Nervous system involvement in coronavirus disease 2019: results from a retrospective consecutive neuroimaging cohort Inter-and intraobserver reproducibility of cerebral atrophy assessment on MRI scans with hemispheric infarcts MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging The Microbleed Anatomical Rating Scale (MARS): reliability of a tool to map brain microbleeds Clinical characteristics and day-90 outcomes of 4244 critically ill adults with COVID-19: a prospective cohort study The Karolinska NeuroCOVID study protocol: Neurocognitive impairment, biomarkers and advanced imaging in critical care survivors